Hypertension and kidney disease: A deadly connection

被引:35
作者
Barri Y.M. [1 ]
机构
[1] Division of Nephrology and Transplantation, Baylor University Medical Center, Dallas, TX 75246
关键词
Chronic Kidney Disease; Diabetic Nephropathy; Blood Pressure Control; Hemodialysis Patient; Blood Pressure Goal;
D O I
10.1007/s11886-006-0098-7
中图分类号
学科分类号
摘要
Kidney disease may be the cause or a consequence of hypertension. Hypertension affects 25% of the adult population in the United States. Similarly, chronic kidney disease (CKD) and end-stage renal disease (ESRD) have been steadily increasing in incidence because of the increasing age of the US population and rise in the incidence of risk factors, including hypertension. Substantial evidence supports the notion that elevated blood pressure is the most significant risk factor for the development of CKD. Microalbuminuria has been shown to be the early marker of hypertensive renal disease. Furthermore, therapy to reduce microalbuminuria was associated with delay in the progression of renal disease. Black Americans are at higher risk for developing hypertensive nephrosclerosis than whites. Hypertension is a major risk factor for cardiovascular events in patients with CKD and ESRD and those who have undergone renal transplantation. Studies have documented that elevated serum creatinine and CKD are risk factors for a cardiovascular event. Tight blood pressure control has been shown to reduce microalbuminuria and proteinuria and to delay progression of renal disease. Tailoring the choice of antihypertensive medication to the clinical setting to achieve a blood pressure goal is critical in reducing complications from this deadly connection. Copyright © 2006 by Current Science Inc.
引用
收藏
页码:411 / 417
页数:6
相关论文
共 40 条
[1]  
Sowers J.R., Epstein M., Frolich E., Diabetes, hypertension and cardiovascular disease: An update, Hypertension, 37, pp. 1053-1059, (2001)
[2]  
Douglas J.G., Clinical guidelines for the treatment of hypertension in African Americans, Am J Cardiovasc Drugs, 5, pp. 1-6, (2005)
[3]  
Chobanian A.V., Bakris G.L., Black H.R., Et al., The Seventh Report of the National Committee Prevention, Detection, Evaluation and Treatment of High Blood Pressure, Hypertension, 42, pp. 1206-1252, (2003)
[4]  
K/Doqi Clinical Practice guidelines on hypertension and antihypertensive agents in chronic kidney disease, Am J Kidney Dis, 43, SUPPL. 1, (2004)
[5]  
Mann J.F., Gerstein H.C., Pogue J., Et al., Renal insufficiency as a predictor of cardiovascular outcomes and the impact of Ramipril: The HOPE randomized trial, Ann Intern Med, 134, pp. 629-636, (2001)
[6]  
Shulman N.B., Fold C.E., Hall W.D., Et al., Prognostic value of serum creatinine and effect of treatment of hypertension on renal function, Hypertension, 13, SUPPL. 5, pp. 180-193, (1989)
[7]  
Walker W.G., Neaton J.D., Cutler J.A., Et al., Renal function change in hypertensive members of the Multiple Risk Factors Intervention Trial. Racial and treatment effects, J Am Med Assoc, 268, pp. 3085-3091, (1992)
[8]  
Peterson J.C., Adler S., Burkart J.M., Et al., Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study, Ann Intern Med, 123, pp. 754-762, (1995)
[9]  
Bakris G.L., William M., Dworkin L., Et al., Preserving kidney function in adults with hypertension and diabetes: A consensus approach, Am J Kidney Dis, 36, pp. 646-661, (2000)
[10]  
Perry Jr. H.M., Miller J.P., Fornoff J.R., Et al., Early predictors of 15-year end-stage renal disease in hypertensive patients, Hypertension, 25, pp. 587-594, (1995)